Enhanced Therapeutic Efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil Resistant Head and Neck Tumours in Relation to 5-fluorouracil Metabolising Enzymes

Overview

Journal Br J Cancer

Specialty Oncology

Date 1989 Mar 1

PMID 2522792

Citations 6

Authors

G J Peters

B J Braakhuis

E A de Bruijn

E J Laurensse

M van Walsum

H M Pinedo

Affiliations

Soon will be listed here.

Abstract

Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR). 5-FU sensitivity at the maximum tolerated dose (MTD) showed the following pattern; HNX-DU less than HNX-KE = HNX-E = HNX-G less than Colon 26 much less than Colon 38. The sensitivity pattern to 5'd-FUR was: HNX-DU less than HNX-G less than HNX-E less than HNX-KE less than Colon 38 less than Colon 26. For HNX-KE, HNX-E and Colon 26 an increase in therapeutic efficacy was observed with 5'd-FUR as compared to 5-FU; Colon 38 was as sensitive to 5'd-FUR as to 5-FU. Plasma pharmacokinetics of 5'd-FUR and 5-FU were comparable in normal and nude mice. Metabolism of 5-FU and 5'd-FUR was studied in the tumours. Conversion of 5'd-FUR to 5-FU was highest in Colon 26 and 15-20 times lower in HNX-DU, HNX-KE and Colon 38. The Km for 5'd-FUR in all tumours was 1-2 mM. Further anabolism of 5-FU to fluorouridine (FUR) was 5-10 times higher than that of 5-FU to FUR in HNX tumours and 3 times in the colon tumours. 5-FU conversion to FUMP via FUR had the following pattern: Colon 26 much greater than HNX-DU greater than HNX-G greater than HNX-E greater than HNX-KE much greater than Colon 38; of 5-FU to FdUMP via FUdR: Colon 26 greater than HNX-DU = HNX-KE greater than HNX-E greater than HNX-G = Colon 38; and that of 5-FU to FUMP catalysed by orotate phosphoribosyl transferase (OPRT); Colon 26 greater than or equal to Colon 38 greater than HNX-KE greater than HNX-E = HNX-DU = HNX-G. Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential sensitivity.

Citing Articles

Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.

Yamashita T, Kato K, Long N, Makita H, Yonemoto K, Iida K Mol Clin Oncol. 2014; 2(3):429-434.

PMID: 24772313 PMC: 3999128. DOI: 10.3892/mco.2014.267.

Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.

Makino H, Uetake H, Danenberg K, Danenberg P, Sugihara K BMC Cancer. 2008; 8:210.

PMID: 18652704 PMC: 2533342. DOI: 10.1186/1471-2407-8-210.

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

De Bruin M, van Capel T, van der Born K, Kruyt F, Fukushima M, Hoekman K Br J Cancer. 2003; 88(6):957-64.

PMID: 12644837 PMC: 2377090. DOI: 10.1038/sj.bjc.6600808.

Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Midoro K, Gotoh K, Houkan T, Yukishige K, Fujiwara K, Ootsu K Jpn J Cancer Res. 1997; 88(3):306-15.

PMID: 9140116 PMC: 5921383. DOI: 10.1111/j.1349-7006.1997.tb00382.x.

New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

van der Wilt C, Peters G Pharm World Sci. 1994; 16(2):84-103.

PMID: 7518280 DOI: 10.1007/BF01880660.

References

Barankiewicz J, HENDERSON J . Determination of ribose 1-phosphate in ascites tumor cells. Biochem Med. 1977; 17(1):45-53. DOI: 10.1016/0006-2944(77)90008-4. View

Braakhuis B, Schoevers E, Heinerman E, Sneeuwloper G, Snow G . Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate. Br J Cancer. 1983; 48(5):711-6. PMC: 2011514. DOI: 10.1038/bjc.1983.254. View

Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama H . Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gan. 1980; 71(1):112-23. View

BOLLAG W, HARTMANN H . Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine. Eur J Cancer (1965). 1980; 16(4):427-32. DOI: 10.1016/0014-2964(80)90221-2. View

Armstrong R, Diasio R . Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res. 1980; 40(9):3333-8. View

Woodman P, Sarrif A, HEIDELBERGER C . Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine. Cancer Res. 1980; 40(3):507-11. View

Wataya Y, Santi D . Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2'-deoxyuridine as substrate. Anal Biochem. 1981; 112(1):96-8. DOI: 10.1016/0003-2697(81)90265-7. View

Armstrong R, Diasio R . Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res. 1981; 41(12 Pt 1):4891-4. View

HARTMANN H, Matter A . Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines. Cancer Res. 1982; 42(6):2412-5. View

10.

Miwa M, Nakamura J, Ishitsuka H . A simple and convenient assay method for phosphorolysis of 5'-deoxy-5-fluorouridine. Gan. 1981; 72(6):965-8. View

11.

Braakhuis B, Sneeuwloper G, Snow G . The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol. 1984; 239(1):69-79. DOI: 10.1007/BF00454264. View

12.

Abele R, Kaplan E, Grossenbacher R, SCHMID H, Cavalli F . Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol. 1984; 20(3):333-6. DOI: 10.1016/0277-5379(84)90078-6. View

13.

Peters G, Laurensse E, Lankelma J, Leyva A, Pinedo H . Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. Eur J Cancer Clin Oncol. 1984; 20(11):1425-31. DOI: 10.1016/0277-5379(84)90063-4. View

14.

Peters G, Laurensse E, Leyva A, Pinedo H . The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. Int J Biochem. 1985; 17(1):95-9. DOI: 10.1016/0020-711x(85)90091-6. View

15.

Braakhuis B, Leyva A, Schoevers E, Boerrigter G, Schornagel J, Snow G . Lack of effect of methotrexate on human head and neck tumours transplanted in athymic nude mice. Acta Otolaryngol. 1985; 99(3-4):208-13. DOI: 10.3109/00016488509108899. View

16.

Choong Y, Lee S . The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues. Clin Chim Acta. 1985; 149(2-3):175-83. DOI: 10.1016/0009-8981(85)90331-6. View

17.

de Bruijn E, Van Oosterom A, Tjaden U, Reeuwijk H, Pinedo H . Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res. 1985; 45(11 Pt 2):5931-5. View

18.

Peters G, Laurensse E, Leyva A, Lankelma J, Pinedo H . Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986; 46(1):20-8. View

19.

Tannock I, Browman G . Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol. 1986; 4(7):1121-6. DOI: 10.1200/JCO.1986.4.7.1121. View

20.

Hurteloup P, Armand J, CAPPELAERE P, Metz R, Kerbrat P, KEILING R . Phase II clinical evaluation of doxifluridine. Cancer Treat Rep. 1986; 70(6):731-7. View